argenx (ARGX) Reports Q1 Loss of EUR1.87
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
argenx reports first quarter 2020 financial results and provides business update
May 14, 2020 1:00 AM EDT            - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year -             -  Enrollment paused in ongoing trials under Janssen and LEO Pharma collaborations  -                         - ARGX-117 being evaluated in COVID-19 patients with acute respiratory distress syndrome in collaboration with UZ Gent
            - Management to host conference call today at 3:00 pm CEST (9:00 am ET) -
May 14, 2020 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of... More
